(Q38259127)

1 September 2017

1 reference

title

Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases (English)

1 reference

1 September 2017

Maria A V Willrich

1

1 reference

1 September 2017

David L Murray

series ordinal

2

1 reference

1 September 2017

Melissa R Snyder

series ordinal

3

1 reference

1 September 2017

publication date

22 September 2014

1 reference

1 September 2017

published in

Translational Research

1 reference

1 September 2017

volume

165

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

270-282

1 reference

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Clinical impact of serum proteins on drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

7 January 2021

Therapeutic proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Heterogeneity of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Preliminary criteria for clinical remission in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Global prevalence of ankylosing spondylitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Adalimumab for the treatment of ankylosing spondylitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Psoriatic arthritis. Clinical manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Treatment of psoriasis and psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Treatment recommendations for psoriatic arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Drug monitoring of biologics in inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Management of Crohn's disease in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Incidence and nature of infectious disease in patients treated with anti-TNF agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Selective TNF-α inhibitor-induced injection site reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Anti-TNF therapy: safety aspects of taking the risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Assessing the safety of biologic agents in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Overview of safety of non-biologic and biologic DMARDs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Infliximab-induced aseptic meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Therapeutic drug monitoring in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.09.006

10.1016/J.TRSL.2014.09.006

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference